Brief Title
Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary
Official Title
Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.
Brief Summary
To assess the effect of long-term treatment by Genotonorm on linear growth
Study Phase
Phase 3
Study Type
Interventional
Primary Outcome
The main efficacy variable is the height SDS (SEMPE) before and after treatment.
Condition
Growth Hormone Deficiency
Intervention
Somatropin
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
14
Start Date
February 1997
Completion Date
October 2006
Eligibility Criteria
Inclusion Criteria: - All the patients who have benefit during one year of a treatment by Genotonorm during the study 94-8123-014 - All patients who have stopped during one year will be included if a signed written informed consent Exclusion Criteria: - Endocrine disease, except well substituted hypothyroidism - Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)
Gender
All
Ages
6 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Pfizer CT.gov Call Center, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT00174278
Organization ID
96-8123-018
Secondary IDs
A6281217
Study Sponsor
Pfizer
Study Sponsor
Pfizer CT.gov Call Center, Study Director, Pfizer
Verification Date
August 2008